 Nicholas Walter
Concepts (105)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Mycobacterium tuberculosis | 15 | 2023 | 268 | 4.910 |
Why?
| | Tuberculosis | 14 | 2023 | 241 | 4.600 |
Why?
| | Antitubercular Agents | 9 | 2023 | 169 | 2.270 |
Why?
| | Tuberculosis, Pulmonary | 6 | 2021 | 112 | 2.060 |
Why?
| | RNA, Ribosomal | 2 | 2021 | 157 | 1.450 |
Why?
| | Sputum | 7 | 2021 | 285 | 1.450 |
Why?
| | RNA, Bacterial | 3 | 2021 | 174 | 1.010 |
Why?
| | RNA Precursors | 1 | 2021 | 136 | 0.700 |
Why?
| | Polymerase Chain Reaction | 1 | 2022 | 995 | 0.650 |
Why?
| | Microbial Viability | 1 | 2018 | 79 | 0.600 |
Why?
| | Transcriptome | 2 | 2023 | 728 | 0.510 |
Why?
| | Cell Membrane | 1 | 2018 | 679 | 0.480 |
Why?
| | Bronchoalveolar Lavage Fluid | 1 | 2016 | 590 | 0.450 |
Why?
| | Energy Metabolism | 1 | 2018 | 724 | 0.430 |
Why?
| | Biomarkers | 3 | 2021 | 3418 | 0.430 |
Why?
| | Drug Therapy, Combination | 2 | 2023 | 954 | 0.340 |
Why?
| | Gene Expression Regulation, Bacterial | 3 | 2023 | 285 | 0.340 |
Why?
| | Anti-Bacterial Agents | 1 | 2018 | 1477 | 0.330 |
Why?
| | Mice, Inbred BALB C | 2 | 2022 | 1152 | 0.320 |
Why?
| | Disease Models, Animal | 3 | 2023 | 3549 | 0.320 |
Why?
| | Gene Expression Profiling | 3 | 2023 | 1523 | 0.310 |
Why?
| | HIV Infections | 6 | 2020 | 2469 | 0.300 |
Why?
| | Communicable Disease Control | 1 | 2008 | 67 | 0.290 |
Why?
| | Mice | 4 | 2023 | 14935 | 0.270 |
Why?
| | Anti-Infective Agents | 2 | 2023 | 225 | 0.260 |
Why?
| | Protein Kinases | 2 | 2017 | 307 | 0.240 |
Why?
| | Transcription, Genetic | 2 | 2023 | 1317 | 0.240 |
Why?
| | Guideline Adherence | 1 | 2008 | 490 | 0.220 |
Why?
| | Mice, Inbred C3H | 1 | 2023 | 242 | 0.210 |
Why?
| | Mice, Inbred Strains | 1 | 2023 | 398 | 0.210 |
Why?
| | Adaptation, Physiological | 2 | 2023 | 483 | 0.200 |
Why?
| | Coinfection | 3 | 2018 | 120 | 0.200 |
Why?
| | Animals | 4 | 2023 | 31837 | 0.190 |
Why?
| | Bacterial Proteins | 2 | 2017 | 739 | 0.190 |
Why?
| | Lung | 2 | 2023 | 3593 | 0.180 |
Why?
| | Uganda | 5 | 2020 | 70 | 0.170 |
Why?
| | Humans | 18 | 2023 | 114925 | 0.160 |
Why?
| | RNA | 2 | 2014 | 810 | 0.150 |
Why?
| | Specimen Handling | 2 | 2016 | 156 | 0.150 |
Why?
| | Female | 8 | 2023 | 59571 | 0.140 |
Why?
| | AIDS-Related Opportunistic Infections | 2 | 2018 | 117 | 0.140 |
Why?
| | Anti-Retroviral Agents | 1 | 2018 | 207 | 0.130 |
Why?
| | Adult | 7 | 2021 | 30604 | 0.130 |
Why?
| | Genes, Bacterial | 1 | 2016 | 157 | 0.130 |
Why?
| | Microscopy | 2 | 2013 | 125 | 0.120 |
Why?
| | Drug Monitoring | 1 | 2016 | 184 | 0.120 |
Why?
| | Latent Tuberculosis | 1 | 2015 | 64 | 0.120 |
Why?
| | Mice, Inbred C57BL | 1 | 2023 | 4718 | 0.120 |
Why?
| | ROC Curve | 1 | 2015 | 448 | 0.120 |
Why?
| | Genome, Bacterial | 1 | 2014 | 106 | 0.110 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2013 | 42 | 0.110 |
Why?
| | Antigens, Fungal | 1 | 2013 | 25 | 0.110 |
Why?
| | Cryptococcosis | 1 | 2013 | 23 | 0.110 |
Why?
| | Real-Time Polymerase Chain Reaction | 1 | 2014 | 316 | 0.110 |
Why?
| | DNA-Binding Proteins | 2 | 2017 | 1317 | 0.110 |
Why?
| | Nystatin | 1 | 2012 | 1 | 0.100 |
Why?
| | Chlorhexidine | 1 | 2012 | 22 | 0.100 |
Why?
| | Oxidative Stress | 1 | 2018 | 1084 | 0.100 |
Why?
| | HIV | 1 | 2012 | 208 | 0.090 |
Why?
| | Pneumonia | 1 | 2015 | 568 | 0.090 |
Why?
| | RNA, Messenger | 1 | 2016 | 2558 | 0.080 |
Why?
| | Case-Control Studies | 1 | 2015 | 3008 | 0.080 |
Why?
| | Male | 6 | 2021 | 55655 | 0.080 |
Why?
| | San Francisco | 1 | 2008 | 56 | 0.080 |
Why?
| | Emigration and Immigration | 1 | 2008 | 44 | 0.070 |
Why?
| | Treatment Outcome | 1 | 2021 | 9105 | 0.070 |
Why?
| | United States | 2 | 2015 | 12209 | 0.070 |
Why?
| | Inpatients | 2 | 2020 | 380 | 0.070 |
Why?
| | Aged, 80 and over | 1 | 2015 | 6363 | 0.060 |
Why?
| | Sensitivity and Specificity | 2 | 2020 | 1700 | 0.050 |
Why?
| | Microbial Sensitivity Tests | 1 | 2023 | 301 | 0.050 |
Why?
| | Benchmarking | 1 | 2023 | 161 | 0.050 |
Why?
| | Young Adult | 1 | 2015 | 10476 | 0.040 |
Why?
| | Middle Aged | 2 | 2018 | 26801 | 0.040 |
Why?
| | C-Reactive Protein | 1 | 2020 | 362 | 0.040 |
Why?
| | Adolescent | 1 | 2015 | 17826 | 0.040 |
Why?
| | Aged | 1 | 2015 | 19120 | 0.040 |
Why?
| | Gambia | 1 | 2017 | 12 | 0.040 |
Why?
| | Ghana | 1 | 2017 | 30 | 0.040 |
Why?
| | Molecular Epidemiology | 1 | 2017 | 62 | 0.030 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2018 | 256 | 0.030 |
Why?
| | World Health Organization | 1 | 2016 | 103 | 0.030 |
Why?
| | Prospective Studies | 2 | 2020 | 6218 | 0.030 |
Why?
| | Cryptococcus | 1 | 2013 | 8 | 0.030 |
Why?
| | Africa | 1 | 2013 | 95 | 0.030 |
Why?
| | Standard of Care | 1 | 2013 | 62 | 0.030 |
Why?
| | HIV-1 | 1 | 2018 | 767 | 0.030 |
Why?
| | Mouthwashes | 1 | 2012 | 12 | 0.030 |
Why?
| | Diagnostic Tests, Routine | 1 | 2013 | 87 | 0.030 |
Why?
| | Oxygen | 1 | 2017 | 853 | 0.030 |
Why?
| | Colony Count, Microbial | 1 | 2012 | 111 | 0.030 |
Why?
| | Survival Rate | 1 | 2016 | 1644 | 0.030 |
Why?
| | Genotype | 1 | 2017 | 1775 | 0.020 |
Why?
| | CD4 Lymphocyte Count | 1 | 2012 | 257 | 0.020 |
Why?
| | Single-Blind Method | 1 | 2012 | 258 | 0.020 |
Why?
| | Cough | 1 | 2012 | 107 | 0.020 |
Why?
| | Mortality | 1 | 2013 | 288 | 0.020 |
Why?
| | Cross-Sectional Studies | 1 | 2020 | 4406 | 0.020 |
Why?
| | Prevalence | 1 | 2016 | 2251 | 0.020 |
Why?
| | Polymorphism, Single Nucleotide | 1 | 2017 | 1893 | 0.020 |
Why?
| | Phenotype | 1 | 2017 | 2817 | 0.020 |
Why?
| | Severity of Illness Index | 1 | 2016 | 2542 | 0.020 |
Why?
| | Practice Guidelines as Topic | 1 | 2016 | 1400 | 0.020 |
Why?
| | Incidence | 1 | 2013 | 2316 | 0.020 |
Why?
| | Time Factors | 1 | 2012 | 6125 | 0.010 |
Why?
|
|
Walter's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|